GlycoMimetics (NASDAQ:GLYC – Get Free Report) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.05, Zacks reports.
GlycoMimetics Trading Up 9.2 %
NASDAQ GLYC opened at $0.28 on Friday. GlycoMimetics has a fifty-two week low of $0.14 and a fifty-two week high of $3.36. The stock has a 50 day simple moving average of $0.26 and a two-hundred day simple moving average of $0.24.
Wall Street Analyst Weigh In
Separately, StockNews.com assumed coverage on GlycoMimetics in a research report on Monday. They set a “sell” rating on the stock.
GlycoMimetics Company Profile
GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.
Featured Articles
- Five stocks we like better than GlycoMimetics
- What is Short Interest? How to Use It
- Silicon Valley’s Sleeping Giant? Intel’s Comeback in Focus
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Upstart’s Uptrend Is Just Getting Started: Its Time to Load Up
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.
